Palatin Tech (PTN) Stock News

Palatin (NYSE: PTN) reported fiscal Q2 2026 results and a corporate update on Feb 17, 2026. The company completed an $18.2M public offering, regained NYSE American compliance, and strengthened its cash position to $14.5M as of Dec 31, 2025, with a cash runway beyond Mar 31, 2027.

Palatin advanced its MC4R obesity programs: oral small-molecule PL7737 targets IND filing and Phase 1 initiation in H1 2026; once-weekly peptide MC4R candidates target IND and Phase 1 in H2 2026. The company received upfronts of €2.0M from Boehringer Ingelheim and $3.8M from a PL9643 sublicense.

Palatin (NYSE: PTN) reported fiscal Q1 2026 results and a corporate update on November 13, 2025. Key developments include a €2.0M upfront payment and a €5.5M research milestone from a Boehringer Ingelheim collaboration, an upsized $18.2M public offering closed November 12, 2025, and reinstatement of NYSE American trading under PTN on November 12, 2025.

Pipeline milestones: IND-enabling toxicology for oral MC4R agonist PL7737 with an IND and Phase 1 SAD/MAD planned for H1 2026; next-generation weekly peptide MC4R agonists planned for IND and Phase 1 in mid-2026. Fiscal Q1 results: $8.85M collaboration revenue and $4.7M net income; cash and equivalents were $1.3M as of September 30, 2025, with expected runway beyond December 31, 2026.

Palatin Technologies (NYSE: PTN) announced the closing of an upsized underwritten public offering on November 12, 2025, raising approximately $18.2 million of gross proceeds following full exercise of the underwriters' over-allotment option. The offering comprised 2,795,384 shares of common stock (or pre-funded warrants) and accompanying Series J and Series K warrants to purchase up to 2,795,384 shares each at a combined public offering price of $6.50 per share with accompanying warrants.

The company may receive up to an additional $18.2 million if milestone-related Series J warrants are cashed, though exercise is not guaranteed. Net proceeds are intended to support the company's obesity program, working capital and general corporate purposes. Closing restored the company's compliance with NYSE American listing standards and resumed trading under the symbol PTN on November 12, 2025.

Palatin (OTCQB: PTN) presented preclinical and clinical data at ObesityWeek® 2025 highlighting melanocortin-4 receptor (MC4R) agonists for obesity treatment.

Key points: oral MC4R candidate PL7737 showed dose-dependent weight loss in DIO mice, ~50% oral bioavailability and >3-hour half-life in rats, and no hERG/Ames findings; IND-enabling toxicology is underway with an IND and Phase 1 SAD/MAD trial planned for H1 2026 and clinical data expected H2 2026. A Phase II study (BMT-801) reported that adding low-dose MC4R agonist to tirzepatide increased weight loss, was well tolerated, and helped prevent weight regain. The FDA granted Orphan Drug Designation to PL7737 for LEPR deficiency–related obesity.

Palatin Technologies (OTCQB: PTNT) has announced a 1-for-50 reverse stock split effective August 8, 2025, at 5:00 p.m. EDT. The stock will begin trading on a split-adjusted basis on August 11, 2025, under the temporary symbol PTNTD for 20 trading days.

The primary objective is to increase the per-share price to meet NYSE American's Listing Qualifications. The reverse split was approved by stockholders on July 25, 2025, with an authorized range of 1-for-50 to 1-for-100. Shareholders will receive cash for any fractional shares, and the company's new CUSIP number will be 696077 601.

Palatin Technologies (OTC PINK: PTNT) reported fiscal Q3 2025 results with significant progress in obesity and ocular programs. Their Phase 2 obesity study combining Bremelanotide with Tirzepatide showed 4.4% weight reduction vs 1.6% for placebo, with 19% of patients achieving ≥7% weight loss. The PL9643 Phase 3 MELODY-1 study in Dry Eye Disease demonstrated unprecedented symptom resolution. However, the company faces challenges as it was delisted from NYSE American due to low stock price, now trading on OTC Pink Market. Financially, Palatin reported a net loss of $4.8 million ($0.18 per share) compared to $8.4 million loss year-over-year. Cash position stands at $2.5 million, with additional $3.5 million raised through ATM facility and equity offering. The company recently closed a $1.1 million public offering of shares and warrants at $0.15 per share.

Palatin Technologies (OTC PINK: PTNT) presented new preclinical data for its melanocortin agonists PL9654 and PL9655 at ARVO 2025, demonstrating promising results for treating diabetic retinopathy (DR). The compounds showed effectiveness in resolving inflammation, stabilizing blood-retinal barriers, reducing VEGF signaling, and protecting retinal ganglion cells. Key findings include vision preservation, inflammation control, retinal protection, and anti-angiogenic properties. Both compounds demonstrated efficacy through multiple administration routes, including topical delivery. This research is particularly significant as DR affects up to 80% of long-term diabetes patients, with CDC projecting U.S. cases to triple from 5.5 million in 2025 to 16 million by 2050. The melanocortin receptor system's role in regulating inflammation and tissue repair makes these compounds promising candidates for treating ocular diseases.

Palatin Technologies (OTC PINK: PTNT) has closed a reduced public offering, raising approximately $1.1 million through the sale of 7,324,119 shares of common stock at $0.15 per share, along with three series of warrants. The offering includes Series F warrants ($0.30 exercise price, 5-year expiry), Series G warrants ($0.15 exercise price, 24-month expiry), and Series H warrants ($0.225 exercise price, 24-month expiry from issuance). The company has transitioned to trading on the OTC Pink market and plans to use the proceeds for working capital and general corporate purposes. A.G.P./Alliance Global Partners led the placement, with Laidlaw & Company as co-placement agent.

Palatin Technologies (OTC PINK: PTNT) presented breakthrough data from its Phase 3 MELODY-1 trial of PL9643 for Dry Eye Disease (DED) at ARVO 2025. The study demonstrated complete symptom resolution across multiple endpoints, with 6 of 13 symptom endpoints reaching statistical significance (p0.05). PL9643 showed rapid onset of action starting at week 2 and continued improvement through week 12. The drug was well-tolerated with adverse event rates comparable to or better than vehicle. The DED market is projected to grow from . Following MELODY-1's success, Palatin plans two additional Phase 3 studies (MELODY-2 and MELODY-3), pending partnership and funding, with enrollment potentially starting in H2 2025 and topline data expected in H2 2026.